Lab on a chip for multiplexed immunoassays to detect bladder cancer using multifunctional dielectrophoretic manipulations

Chuang, Cheng-Hsin; Wu, Tingfeng; Chen, Cheng-Ho; Chang, Kai‐Fu; Ju, Jing-Wei; Huang, Yao-Wei; Nhan, Vo Van

doi:10.1039/c5lc00352k

Cited by 34 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, a multiplexed immunosensor has been developed for the detection of specific biomarkers galectin-1 and lactate dehydrogenase B present in different grades of bladder cancer cell lysates. This approach has allowed not only the identification of different grades of bladder cancer cells but also the real time detection of multiple analytes on a single chip, providing more practical benefits for clinical diagnosis [ 238 ].…”

Section: Exploring Glycans For Non-invasive Bladder Cancer Detectionmentioning

confidence: 99%

Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

et al. 2017

View full text Add to dashboard Cite

The high molecular heterogeneity of bladder tumours is responsible for significant variations in disease course, as well as elevated recurrence and progression rates, thereby hampering the introduction of more effective targeted therapeutics. The implementation of precision oncology settings supported by robust molecular models for individualization of patient management is warranted. This effort requires a comprehensive integration of large sets of panomics data that is yet to be fully achieved. Contributing to this goal, over 40 years of bladder cancer glycobiology have disclosed a plethora of cancer-specific glycans and glycoconjugates (glycoproteins, glycolipids, proteoglycans) accompanying disease progressions and dissemination. This review comprehensively addresses the main structural findings in the field and consequent biological and clinical implications. Given the cell surface and secreted nature of these molecules, we further discuss their potential for non-invasive detection and therapeutic development. Moreover, we highlight novel mass-spectrometry-based high-throughput analytical and bioinformatics tools to interrogate the glycome in the postgenomic era. Ultimately, we outline a roadmap to guide future developments in glycomics envisaging clinical implementation.

show abstract

Section: Exploring Glycans For Non-invasive Bladder Cancer Detectionmentioning

confidence: 99%

Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Bladder cancer was studied by multiplexed microfluidic immunoassay using DEP [92,93] and MGE-LIF [94].…”

Section: Bladder Cancermentioning

confidence: 99%

A decade of microchip electrophoresis for clinical diagnostics – A review of 2008–2017

Wuethrich

Quirino

2019

Analytica Chimica Acta

View full text Add to dashboard Cite

A core element in clinical diagnostics is the data interpretation obtained through the analysis of patient samples. To obtain relevant and reliable information, a methodological approach of sample preparation, separation, and detection is required. Traditionally, these steps are performed independently and stepwise. Microchip capillary electrophoresis (MCE) can provide rapid and high-resolution separation with the capability to integrate a streamlined and complete diagnostic workflow suitable for the point-of-care setting. Whilst standard clinical diagnostics methods normally require hours to days to retrieve specific patient data, MCE can reduce the time to minutes, hastening the delivery of treatment options for the patients. This review covers the advances in MCE for disease detection from 2008 to 2017. Miniaturised diagnostic approaches that required an electrophoretic separation step prior to the detection of the biological samples are reviewed. In the two main sections, the discussion is focused on the technical setup used to suit MCE for disease detection and on the strategies that have been applied to study various diseases. Throughout these discussions MCE is compared to other techniques to create context of the potential and challenges of MCE. A comprehensive table categorised based on the studied disease using MCE is provided. We also comment on future challenges that remain to be addressed.

show abstract

“…In addition, Gal-1 expression positively correlated with pT classification, histological grade, vascular invasion, and nodal status 31 . Accordingly, the development of Gal-1-based assays for bladder cancer detection for clinical use is now of particular interest, and the first prototypes have been developed and assessed using bladder cancer cell extracts 163 .…”

Section: [H2] Gal-1 In Bladder Cancermentioning

confidence: 99%

Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

et al. 2019

View full text Add to dashboard Cite

Advanced prostate and bladder cancer are two outstanding unmet medical needs for urological oncologists. The high prevalence of these tumours, lack of effective biomarkers, and limited effective treatment options highlight the importance of basic research in these diseases. Galectins are a family of β-galactoside-binding proteins that are frequently altered (upregulated or downregulated) in a wide range of tumours and have roles in different stages of tumour development and progression, including immune evasion. In particular, altered expression levels of different members of the galectin family have been reported in prostate and bladder cancers, which, together with the aberrant glycosylation patterns found in tumour cells and the constituent cell types of the tumour microenvironment, can result in malignant transformation and tumour progression. Understanding the roles of galectin family proteins in the development and progression of prostate and bladder cancer could yield key insights to inform the clinical management of these diseases.

show abstract

Lab on a chip for multiplexed immunoassays to detect bladder cancer using multifunctional dielectrophoretic manipulations

Cited by 34 publications

References 27 publications

Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

A decade of microchip electrophoresis for clinical diagnostics – A review of 2008–2017

Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

Contact Info

Product

Resources

About